MENU
+Compare
NGENF
Stock ticker: OTC
AS OF
Aug 15 closing price
Price
$2.12
Change
-$0.08 (-3.64%)
Capitalization
152.72M

NGENF NervGen Pharma Corp. Forecast, Technical & Fundamental Analysis

NervGen Pharma Corp is a clinical-stage biotech company... Show more

NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NGENF with price predictions
Aug 15, 2025

NGENF sees MACD Histogram crosses below signal line

NGENF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 25, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NGENF as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

NGENF moved below its 50-day moving average on July 16, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGENF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NGENF entered a downward trend on August 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

NGENF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NGENF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGENF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NGENF's P/B Ratio (151.515) is slightly higher than the industry average of (19.528). P/E Ratio (0.000) is within average values for comparable stocks, (52.377). NGENF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.945). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (294.394).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
112-970 Burrard Street
Phone
+1 778 731-1711
Employees
N/A
Web
https://www.nervgen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCSAX27.18N/A
N/A
Goldman Sachs Small Cap Eq Insghts A
HIMDX23.95N/A
N/A
Hennessy Cornerstone Mid Cap 30 Instl
GSMVX16.70N/A
N/A
Goldman Sachs Small/Mid Cap Equity Instl
MRVNX2.04N/A
N/A
Mirova International Megatrends N
PARWX57.32-0.17
-0.30%
Parnassus Value Equity Investor

NGENF and Stocks

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
-3.77%
CYTK - NGENF
25%
Poorly correlated
-0.13%
IBRX - NGENF
23%
Poorly correlated
-5.90%
TNFA - NGENF
22%
Poorly correlated
-1.27%
CARM - NGENF
22%
Poorly correlated
+2.35%
ATRA - NGENF
22%
Poorly correlated
+4.86%
More